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Abstract
Background Assessing haemodynamic congestion
based on filling pressures instead of clinical conges-
tion can be a way to further improve quality of life
(QoL) and clinical outcome by intervening before
symptoms or weight gain occur in heart failure (HF)
patients. The clinical efficacy of remote monitoring of
pulmonary artery (PA) pressures (CardioMEMS; Ab-
bott Inc., Atlanta, GA, USA) has been demonstrated in
the USA. Currently, the PA sensor is not reimbursed
in the European Union as its benefit when applied in
addition to standard HF care is unknown in Western
European countries, including the Netherlands.
Aims To demonstrate the efficacy and cost-effective-
ness of haemodynamic PA monitoring in addition
to contemporary standard HF care in a high-quality
Western European health care system.
Methods The current study is a prospective, multi-
centre, randomised clinical trial in 340 patients with
chronic HF (New York Heart Association functional
class III) randomised to HF care including remote
monitoring with the CardioMEMS PA sensor or stan-
dard HF care alone. Eligible patients have at least one
hospitalisation for HF in 12 months before enrolment
and will be randomised in a 1:1 ratio. Minimum fol-
low-up will be 1 year. The primary endpoint is the
change in QoL as measured by the Kansas City Car-
diomyopathy Questionnaire (KCCQ). Secondary end-
points are the number of HF hospital admissions and
changes in health status assessed by EQ-5D-5L ques-
tionnaire including health care utilisation and formal
cost-effectiveness analysis.
Conclusion The MONITOR HF trial will evaluate
the efficacy and cost-effectiveness of haemodynamic
monitoring by CardioMEMS in addition to standard
HF care in patients with chronic HF. Clinical Trial
Registration number NTR7672.
Keywords CardioMEMS · e-Health · Heart failure ·
Telemonitoring · Therapy · Trial
Introduction
In Western European countries such as the Nether-
lands, chronic heart failure (HF) is estimated to occur
in 1.5–2.0% of the population [1, 2]. In the Nether-
lands, the prevalence was 227,000 patients in 2017,
and the number of HF hospital admissions is high
at 29,011 admissions per year with an average hos-
pital stay of 9 days [1, 2]. The overall hospital bur-
den from HF hospitalisations will rise rapidly in the
coming decade due to aging of the population and
better survival following myocardial infarctions. The
main public and personal burden of HF is clustered
in patients with New York Health Association (NYHA)
functional class III and IV, who most often need to
be hospitalised. Approximately 25% of all Dutch HF
patients are in NYHA class III based on the latest
CHECK HF registry findings [3]. Contemporary treat-
ment of chronic HF shows a reasonably high adher-
ence to European guidelines for the recommended
drugs, when compared to US data in the CHAMP-HF
registry [4, 5]. Still, both registries show considerable
room for improvement in HF therapy considering tar-
get or optimal dosing of medication [4, 5]. So clearly,
despite optimal medical treatment, there is a consid-
erable residual risk, especially for patients in NYHA
class III. The main problem for care givers and pa-
tients is timely recognition of a daunting cardiac de-
compensation and, if recognised, to react adequately
and promptly.
Remote monitoring and telemonitoring initiatives
have received wide attention for their promise in de-
tecting early signs of decompensation and guiding HF
therapy. Proactive guided treatment could optimise
treatment further and prevent clinical deterioration.
Such an approach could reduce HF hospitalisations
and relieve the large burden of chronic HF exacerba-
tions for the current health care systems. However,
numerous telemonitoring programmes which were
based on remote signs of clinical congestion such
as weight or symptoms or impedance measurements
through pacemakers have been largely disappointing
[6–15]. From a physiological point of view, weight gain
and symptoms of HF are late signs of an exacerbation
of HF. New management strategies should focus on
markers preceding the exacerbation of HF. It has been
recognised that a period of decompensation starts
with a rise in (intracardiac) filling pressures. A chain
of events from haemodynamic (asymptomatic) con-
gestion transits to clinical congestion.
CardioMEMS (Abbott Inc., Atlanta, GA, USA) is
a small sensor capable of measuring pressures in the
pulmonary artery (PA) on a daily basis. PA pressures
can be used as an invasive haemodynamic surrogate
marker of filling pressures, which has been shown
to precede a period of decompensation for several
weeks. This time window would allow the physician
to intervene before clinical symptoms arise and act
in a proactive way to avert an exacerbation of HF by
adjusting the dose of diuretics or vasodilators. In line
with this hypothesis, the CHAMPION trial in the USA
demonstrated a significant 37% reduction in HF hos-
pitalisations with PA monitoring applied in addition
to standard care in patients with chronic HF [16, 17].
Observations in post-marketing studies (with histor-
ical controls) were consistent and confirm the low-
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Fig. 1 Participating centres in the Netherlands
risk and safe procedure as well as the durability of
the device [17–20]. Despite the innovation in patient
management, several profound differences exist in
the organisation of HF care (HF outpatient clinic and
HF nurses), level of standard care, as well as financial
structure of the health care systems in Europe and
the USA, which mean that the results of this one trial
cannot be translated directly. Additionally, individ-
ual trial data in a European setting are lacking and
clinical and financial data can only be extrapolated
from US data [21, 22], in the knowledge that the
costs and setup of the US health care system are not
comparable to the European situation. We therefore
designed the MONITOR HF randomised clinical trial
to evaluate the effectiveness and cost-effectiveness
from a European perspective in the Netherlands.
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Table 1 Inclusion criteria. In order to be eligible to participate in this study, a subject must meet all of the following criteria
1 Written informed consent obtained from subject aged ≥18 years
2 Diagnosis of chronic heart failurea (≥3 months) in NYHA functional class III with 1 HF hospitalisation within 12 months (defined as an admission
for HF longer than 6h and/or use of i.v. diuretics) or emergency ward visit for HF resulting in i.v. diuretic therapy (independent of EF %)
3 HF subjects with reduced EF (HFrEF) should be treated according to national and international (ESC) guidelines for optimal or maximum tolerated
doses of HF medication and evaluated for ICD or CRT-D therapy, if indicated
4 Subjects with a BMI≤ 35. Subjects with BMI> 35 will require their chest circumference to be measured at the axillary level< 65 inches or 165
centimetre (related to distance of the sensor to the pillow)
5 Subjects willing and able to comply with the follow-up requirements of the study and able to comply with the daily readings
aAccording to the definition given in the 2016 ESC guidelines for heart failure [10]. In line with good clinical practice, a patient cannot participate in any other
interventional study or active telemonitoring programme (on HF parameters) during the study
NYHA New York Heart Association, HF heart failure, EF ejection fraction, ESC European Society of Cardiology, ICD implantable cardioverter-defibrillator,
CRT-D cardiac resynchronization therapy defibrillator, BMI body mass index
Table 2 Exclusion criteria
1 Subjects with an active infection
2 Subjects with a history of recurrent (>1) pulmonary embolism or deep vein thrombosis
3 Subjects who have had a major cardiovascular event (e.g. myocardial infarction, open heart surgery, stroke) within the past 2 months
4 Subjects with a CRT implanted <3 months prior to enrolment and implantation of the sensor (in order to avoid manipulation of lead)
5 Subjects with an estimated GFR< 25ml/min (obtained within 2 weeks of the baseline visit), refractory to diuretic therapy, or on chronic renal
dialysis
6 Subjects with complex congenital heart disease or mechanical right heart valve(s)
7 Subjects with known pulmonary arterial hypertension (WHO category 1 or 4/5) in whom PA pressure is most likely not responsive to cardiac
treatment
8 Subjects scheduled for or likely to undergo heart transplantation or receive a ventricular assist device within 6 months of baseline visit
9 Subjects with known coagulation disorders or allergy to acetylsalicylic acid and/or clopidogrel
CRT cardiac resynchronisation device, GFR glomerular filtration rate, PA pulmonary artery
Methods
Study design
The MONITOR HF trial is an investigator-initiated,
multicentre, randomised clinical trial enrolling 340
patients with chronic HF NYHA class III and at least
one HF hospitalisation in the previous 12 months. In
total, 20 Dutch hospitals, distributed over the country,
agreed to participate (Fig. 1; Electronic Supplemen-
tary Material, Appendix Tab. 1). Sites without previous
experience with CardioMEMS will go through a learn-
ing curve of two patients for sensor implantation and
pressure management, who do not participate in the
main trial but are followed according to study pro-
tocol. Alternatively, added centres can proctor two
patients in an experienced centre. The MONITOR HF
trial aims to test the effect of PA monitoring in addi-
tion to standard HF care on quality of life (QoL), the
number of HF hospitalisations and cost-effectiveness
in a Dutch health care system. Four populations for
analysis are defined in the MONITOR HF trial: inten-
tion-to-treat, as-treated and per-protocol (time until
implant after randomisation (maximum 3 weeks per
protocol)) and safety analysis. The principal analy-
sis for the primary effectiveness endpoint will be per-
formed in the intention-to-treat population.
The MONITOR HF trial is sponsored by the Dutch
Ministry of Health and National Health Care Insti-
tute (Zorginstituut, Nederland) as part of a condi-
tional coverage programme in the Netherlands for the
health-care-related costs. The study and data man-
agement are performed by the CRO Erasmus MC Uni-
versity Medical Centre (Sponsor).
Type of patients
Patients with chronic HF (≥3 months) in NYHA func-
tional class III and at least one hospitalisation for HF
(or emergency ward visit resulting in intravenous di-
uretic therapy) in the 12 months prior to enrolment
are eligible for the trial. The diagnosis of HF is made
according to the criteria set out in the 2016 European
Society of Cardiology (ESC) guidelines for the treat-
ment of HF [23]. Patients with HF and reduced ejec-
tion fraction (HFrEF), mid-range (HFmrEF) or pre-
served ejection fraction (HFpEF) are eligible for the
trial. The inclusion and exclusion criteria are pre-
sented in Tab. 1 and 2.
Randomisation
At the baseline visit, patients will be randomised in
a 1:1 ratio for standard care plus CardioMEMS PA
monitoring versus standard HF care with written and
signed informed consent. Crossover is not allowed
per study protocol and leads to termination of the pa-
tient’s participation in the study. After randomisation,
the sensor is to be implanted within 3 weeks per pro-
tocol in those randomised to CardioMEMS and a sec-
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Fig. 2 a The CardioMEMS sensor (with permission of Abbott
Inc.). b The CardioMEMSHF system patient unit including an-
tenna (with permission of Abbott Inc.). c Location of the Car-
dioMEMS sensor in the left pulmonary artery (with permission
of Abbott Inc.)
ond informed consent form will be signed for use of
the Merlin.net website.
CardioMEMS system
The CardioMEMS HF system includes an implantable
wireless sensor with delivery catheter, a patient and
hospital electronics system and a patient database
(Integrated Merlin.net website for patient data man-
agement) [16]. The sensormeasures PA pressure using
MEMS (micro-electromechanical systems) technology
and requires neither battery nor leads (wireless). The
sensor is implanted in a branch of the left PA via
a transvenous catheter inserted through the femoral
vein. The sensor is 15mm in length, 3.4mm in width
and 2mm thick. The sensor remains in the PA as
a permanent implant which endothelialises com-
pletely (Fig. 2). A 4-week course of acetylsalicylic acid
and clopidogrel is recommended in those patients
without anticoagulation or platelet inhibition [16].
Clinicians are informed about the daily CardioMEMS-
derived PA and PA trends over time via Merlin.net
(diagnostic tool in disease management). A study
operating procedure will be available for clinicians to
help them guide HF therapy, most importantly based
on a significant rise in PA pressure over time, aiming
for normal PA pressures avoiding progressive clinical
congestion, or additionally, a significant fall in PA
pressure over time avoiding chronic hypovolaemic
triggers. The device is FDA approved and CE marked
for use in chronic HF patients in NYHA class III
and with one HF hospitalisation in the previous year
(NYHA classes, Tab. 3).
Table 3 New York Health Association classification of heart failure symptoms
NYHA class I Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. no shortness of breath when walking, climbing
stairs etc
NYHA class II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity
NYHA class III Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20–100m). Com-
fortable only at rest
NYHA class IV Severe limitations. Experiences symptoms even while at rest.
Mostly bedbound patients
Standard care
In patients with HFrEF, standard care is defined as
treatment according to the recommendations in the
national and ESC guidelines for HF with up-titrat-
ing recommended HF therapies to maximum toler-
ated or optimal dosages and to evaluate the patient
for an ICD/CRT-D when indicated [23]. For HFpEF
(and HFmrEF) treatment recommendations are lack-
ing, but in accordance with the 2016 ESC guidelines it
is advised to focus on optimal management of comor-
bidities and cardiovascular risk factors such as hyper-
tension and atrial fibrillation [23]. All Dutch hospitals
have a structured HF outpatient clinic with specialised
HF nurses who are supervised by a cardiologist with
experience or specific interest in HF treatment. At
these outpatient clinics, patients are seen for the up-
titration of HF drug therapies at frequent intervals to
reach optimal or maximum tolerated dosages of ev-
idence-based medication. Treatment choices are at
the discretion of the physician. Further, patients are
counselled, e.g. about the aetiology of their HF, diet,
fluid and salt restrictions, as well as the importance of
treatment compliance and of abstaining from tobacco
use and minimising alcohol consumption. Patients
are instructed when to contact the outpatient clinic in
case of alarming symptoms or abnormal weight gain.
After hospital discharge, patients are generally seen by
the HF nurse within 2 weeks, and we estimate that pa-
tients visit these outpatient clinics on average 3 times/
year to see the nurse and at least 2 times/year to see
the cardiologist depending on their clinical need and
ongoing therapeutic decisions.
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Fig. 3 The MONITOR




We hypothesise that the CardioMEMS HF system
applied in addition to standard care will improve




The planned inclusion phase is 24 months. Twenty
centres have initially been selected to start including
patients in this study. In anticipation of a stable in-
clusion rate, we calculate a mean inclusion rate of
0.7 patients per centre per month to reach a sample
size of 340 patients in 2 years. Patient inclusions are
competitive between centres. If, at 6 months, the in-
clusion rate is lower than 50% of that expected, the
number of sites can be increased, if necessary.
Duration of follow-up
All patients will be followed for at least 12 months,
resulting in a minimum follow-up of 12 months (for
the last patient included) and a maximum follow-up
of 36 months (for the first patient included) accord-
ing to the above-mentioned enrolment schedule. The
follow-up visits are scheduled at 3, 6, and 12 months
and every 6 months thereafter (Fig. 3).
Patient visits
At baseline demographics, medical history and medi-
cation use are evaluated. An echocardiogram is part of
the baseline visit (type of HF) as well as a detailed lab-
oratory assessment, QoL questionnaires (Kansas City
Cardiomyopathy Questionnaire (KCCQ) and EQ-5D-
5L) and a 6-min walk test (6MWT) [24, 25]. During fol-
low-up visits, an electrocardiogram (ECG) is recorded
in all patients, NYHA class is established, and a phys-
ical examination is performed, including vital param-
eters and standard laboratory assessments, which will
consist of renal function and natriuretic peptides (NT-
proBNP or BNP). Serum samples are stored at regular
intervals for a biobank at Durrer Center for Cardiovas-
cular Research. A 6MWT is performed at baseline, 6
and 12 months of follow-up. Serial echocardiography
is performed at baseline, 12 months and 24 months
of follow-up. The KCCQ is performed at baseline, 3,
6 and 12 months, EQ-5D-5L at baseline, 3, 6, 12 and
24 months of follow-up. An iMTA Medical Consump-
tion Questionnaire (iMCQ) for health care utilisation
and health technology assessment (HTA) analyses is
performed prospectively at 3, 6 and 12 months [26].
Changes in medication and reasons for change are
recorded in a detailed logbook. In another detailed
logbook, information on patient contacts is recorded,
including the reason for contact, direction of contact
and location (telephone, general practitioner, outpa-
tient clinic, emergency ward, clinic).
Outcome measures
Primary endpoint: Change in QoL as assessed with the
KCCQ HF questionnaire
The KCCQ questionnaire is conducted at baseline
(t= 0), and at follow-up intervals of 3, 6 and 12months’
follow-up after randomisation in both treatment arms.
Primary analysis is based on change in KCCQ scores at
12 months (Tab. 4). The KCCQ questionnaire assesses
QoL in HF patients and has undergone extensive
validation in HF populations [27, 28].
Secondary endpoints
 The number of HF hospitalisations during follow-
up, defined as an unscheduled admission for HF
longer than 6h and/or the need for intravenous
diuretics for decongestion of the patient.
 Change in health status as assessedwith the EQ-5D-
5L questionnaire.
Other endpoints will be all-cause mortality; all-cause
hospitalisations; scheduled HF hospitalisations, com-
posite of all-cause mortality and cumulative HF hos-
pitalisations; cardiovascular mortality; days alive out-
side of the hospital; days in hospital; emergency ward
visits (or equivalent), composite of HF hospitalisations
and emergency ward visits for HF, change in NYHA
class, health care utilisation, number of patient con-
tacts, change in baseline PA pressure; number of med-
ication changes.
A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to. . .
Original Article – Design Study Article
Table 4 Study endpoints
Primary
endpoint
Quality of life as measured by the KCCQ HF questionnaire
at 12 months’ follow-up
Secondary
endpoint
The number of HF hospitalisations during follow-up
Health status as measured by the EQ-5D-5L questionnaire
KCCQ Kansas City Cardiomyopathy Questionnaire, HF heart failure
Statistical analysis
Sample size
The conditional coverage agencies requested 90%
power on QoL endpoints and at least 85% for the sec-
ondary endpoint HF admissions in order to have ad-
equate estimates of effect sizes for cost-effectiveness
analyses (which are dependent on this set of vari-
ables). We decided to aim for 90% statistical power
to detect an at least 6-point difference in KCCQ over-
all summary (KCCQ-OS) score between randomised
treatment groups [27]; we calculated, at an alpha level
of 0.05 and standard deviation (SD) of 15, group sizes
of N1 133 and N2 133 patients (total sample size 266
patients). With an anticipated 10% withdrawal rate,
we will need to include 292 patients in total. For the
secondary endpoint of HF admissions, we used two
assumptions of estimated treatment effect size and
estimated event rates of HF hospitalisations in the
Netherlands. The long-term results of the CHAM-
PION trial, more comparable to our follow-up length,
showed a reduction of 33% in HF hospitalisations
compared to controls (182 HF hospitalisations vs 279
HF hospitalisations, in 270 and 280 patients treated
with CardioMEMS vs standard care, respectively; av-
erage follow-up 18 months) and the Dutch COACH
trial provided an event rate of 2.03% per month in
a comparable but slightly less sick cohort of chronic
HF patients [16, 17, 29]. Under these assumptions,
at least 85% statistical power at an alpha level of
0.05, and a treatment effect size of CardioMEMS of
33% and event rate of 2.0% per month in the control
group, when N1 164 and N2 164 patients, a total of
328 patients is to be included. For the secondary
endpoint, EQ-5D-5L improvement in health status,
90% statistical power to detect a significant difference
of 0.06at an alpha level of 0.05 and SD 0.18, a sample
size of N1 155 and N2 155 totalling 310 patients is
needed, and by including a 10% early withdrawal rate
a total sample size of 340 patients is to be included.
Therefore, the total sample size of the trial required
to adequately answer the research questions is 340
patients.
Data analysis
Data will be summarised using univariate statistics
(number, mean, standard deviation, median) or fre-
quency (number, percentage). For baseline character-
istics, between-group comparisons will be performed
with the χ2 test for categorical variables and two-
sample t-tests for continuous variables. The primary
time-point for effectiveness analyses on improvement
of QoL is 12 months. Change in the KCCQ-OS from
baseline to 12 months will be compared between the
intervention and standard care groups. Additionally,
a linear mixed-effects model will be used to compare
change in the KCCQ-OS over time between the ran-
domly allocated treatment groups to account for miss-
ing data and longitudinal trends. The effect of Car-
dioMEMS in comparison to standard care in changes
of KCCQ clinical summary and KCCQ-OS scores is
compared using repeated measurement analysis of
covariance adjusted for baseline KCCQ score. EQ-5D-
5L scores will be analysed in a comparable manner.
The secondary endpoint in the study is the number
of HF hospitalisations during follow-up. A Cox pro-
portional hazard regression model with Anderson-Gill
method for recurrent events will be used for analy-
sis of clinical events (HF hospitalisations, mortality
rates). Additionally, Cox proportional hazard models
are implemented to analyse time to first events, in-
cluding mortality and hospitalisation. Hospitalisation
rates and mortality rates are estimated using the Ka-
plan-Meier method, and p-values are computed using
the log-rank test. All reported analyses are performed
using the intention-to-treat principle. All statistical
tests will be 2-sided with a significance level of 0.05.
Cost-effectiveness analysis
The cost-effectiveness analyses will be conducted
in accordance with the Dutch guidelines for HTA
and will calculate incremental-cost-effectiveness ratio
(ICER) per quality-adjusted-life-year (QALY) gained
both from a societal as well as health care perspec-
tive. For cost-effectiveness analyses, the EQ-5D-5L
is the required standard tool to use. In addition,
iMCQ, a generic instrument for measuring medical
costs [26], will be used together with costs from the
Dutch costing manual [28]. Cost-effectiveness will be
evaluated by use of a decision analytical model, e.g.
a Markov cohort simulation, developed to capture the
clinical events and costs for the current and a (hypo-
thetical) cohort of patients. The number of states (e.g.
alive or dead; NYHA class; hospitalised; after a cardio-
vascular event) and transitions between these states
distinguished in the cost-effectiveness model will be
chosen based upon the available evidence regarding
the natural history of disease and treatment pathways.
Survival probabilities beyond the trial period can be
estimated by fitting a parametric survival model to
the trial data. For patients who are alive, the period of
survival can be weighted by patients’ utility measured
with the EQ-5D-5L. Similarly, the out-of-hospital pe-
riod will be weighted by patient utility EQ-5D-5L.
Missing data in the EQ-5D-5L questionnaires can be
adjusted for using linear effect models or multiple
imputations. Costs evaluated in the model included
those for sensor implantation and device, care, HF
hospitalisation, medication changes, number of visits,
and end-of-life support for those who died. To ex-
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trapolate costs beyond follow-up, we will make use of
standardised estimates of health-care spending from
the Netherlands [30]. Total costs and QALYs will be
modelled according to the time (in intervals) patients
spent in each health state. The ICER will be evaluated
against the appropriate severity-weighted threshold
for cost-effectiveness.
Trial structure, registration and organisation
The MONITOR HF trial is designed, implemented
and overseen by an independent executive board
and steering committee. The study was evaluated
by scientific committees (ZonMW) and councils of
the National Health Care Institute and patient coun-
cils. Site and data management is performed by the
CRO Erasmus MC trial organisation. An independent
data safety monitoring board (DSMB) has been es-
tablished and will review safety data on an ongoing
basis during the trial in accordance with the DSMB
charter. An independent clinical endpoint committee
(CEC) has been established, blinded to study group
assignment, and will review and adjudicate all deaths
and hospitalisations using prospectively defined cri-
teria in the CEC charter. The adjudicated data are
used for outcomes regarding hospitalisations and
deaths. The DSMB and CEC are organised and led
by an external independent organisation (Cardialy-
sis, Clinical Trial Research Centre). The clinical trial is
structurally monitored by independent monitors from
the research trial organisation. The study complies
with good clinical practice in accordance with the
Declaration of Helsinki and the laws and regulations
applicable in the Netherlands, including the Euro-
pean Union General Data Protection Regulations, as
the clinical trial has been approved by the appropriate
medical ethics committee and review board (Erasmus
MC, MEC 2018-1563). The clinical trial was regis-
tered under the number NL7430 (NTR7672, clinical
trial registration number) on 12 December 2018. The
study started enrolment on 1 April 2019.
Discussion
This multicentre, randomised clinical trial (MONITOR
HF) will evaluate the efficacy and cost-effectiveness of
remote PA monitoring with CardioMEMS applied in
addition to standard care in patients with chronic HF,
from a European perspective. The benefits of remote
monitoring with CardioMEMS were demonstrated in
the CHAMPION trial of 550 participants in the US,
who were studied between 2007 and 2009 [14], and
have been confirmed in several large-scale post-mar-
keting registries [15–17]. The MONITOR HF trial will
provide contemporary trial data on the effectiveness
of CardioMEMS in a highly organised European health
care system where HF patients are routinely followed
in dedicated HF outpatient clinics after an HF admis-
sion. The recently published CHAMP-HF and CHECK-
HF registries highlight the differences in guideline ad-
herences between the Netherlands and the USA [3–5].
Additionally, profound differences exist between Eu-
rope and the USA as regards the organisation of health
care as well as financial structures. The current study
will provide the individual data necessary to perform
calculations on cost-effectiveness of remote monitor-
ing from a European health care perspective.
In the CHAMPION trial, QoL was not a primary
endpoint and data are only available on small subsets
of patients with a short follow-up [16]. The current
trial has QoL as a primary endpoint, which is a novel
aspect in telemonitoring but is emerging as a relevant
clinical endpoint in HF trials. Additionally, QoL might
hypothetically be valued most by the patient, as liv-
ing longer in poor health might not be the main focus
of choice. For the secondary endpoint, the number
of HF hospitalisations, it is most likely that rehospi-
talisation rates differ between the USA and Europe,
and we expect a lower event rate in the Dutch health
care system with dedicated HF nurses and HF outpa-
tient clinics as the organisation of standard care differs
[29]. Dedicated HF outpatient clinics and structured
HF care after HF admissions are emerging through-
out Europe as standard HF care, including multidisci-
plinary team approaches, heart teams, and cardiac re-
habilitation programmes as advocated in the 2016 ESC
guidelines [23]. The recently published US Post Ap-
proval Study (PAS) confirms the consistent treatment
benefit with CardioMEMS in chronic HF patients, re-
ducing the number of HF hospitalisations in a more
contemporary setting [20]. However, the patients in-
cluded in the PAS study were their own historical con-
trols and no randomised comparison to standard care
without PA monitoring was made. However, the main
inference of the PAS is the consistent safety of the im-
plantation procedure and the durability of the sensor
without sensor failures [20].
From a financial point of view, a cost-effectiveness
analysis using the US CHAMPION trial data calcu-
lated an ICER for costs per QALYs of $29,593 for Car-
dioMEMS based on US health care data [21]. Extrap-
olating the US data to European health care systems,
such as those in the UK, the Netherlands and Ger-
many, showed that PA-pressure-guided HF therapy is
anticipated to be cost-effective, but the intervention
increases costs compared with usual care by £10,916
over a time horizon of 10 years while the ICER is es-
timated to be £19,274 with a reduction in admissions
[22]. The analysis did not include staff time, due to
a lack of data concerning this variable. Running the
model with estimated staff time included resulted in
an increased ICER of between £22,342 and £25,464 per
QALY gained [22]. No individual data from European
systems are currently available.
A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to. . .
Original Article – Design Study Article
Other forms of telemonitoring and available
evidence
Several studies have been performed using non-
haemodynamic parameters of remote monitoring
such as signs and symptoms of HF, blood pressure
or daily weights. These studies have shown no ef-
fect on HF hospitalisations [6–15]. Clearly, simple
markers such as weight or blood pressure are inade-
quate for monitoring fluid status and if the variation
in weight is caused by decompensation, treatment
comes too late and cannot prevent a hospitalisation.
Additionally, some studies have investigated natri-
uretic peptides to guide HF therapy, but these were
not successful in reducing HF hospitalisations [10].
Other studies with non-haemodynamic parameters of
remote monitoring have focused on information from
ICD devices using intrathoracic impedance or other
specific combinations of parameters in algorithms
[13–15]. None of these studies have shown any actual
benefit in reducing the number of hospitalisations.
Most recently, the TIM-HF 2 trial was one of the first
studies to show a small benefit of remote monitoring
in HF patients with regard to length of hospital stay,
despite its labour intensity (fully staffed telemedicine
centre)[11].
The 2016 ESC guidelines report on the lack of con-
sistent evidence for non-haemodynamic telemonitor-
ing or remote monitoring in HF patients. The guide-
lines state that remote monitoring may be considered
in selected patients to improve HF outcome with indi-
vidual approaches such as CardioMEMS to reduce the
risk of HF admissions and multi-parameter monitor-
ing with ICD (in-time approach) to improve outcome
in HFrEF with a level IIb class B recommendation [23].
Future developments and potential impact
The most essential concept remains the shift from re-
mote monitoring with (late) signs of clinical conges-
tion to parameters of (early) haemodynamic conges-
tion, which precede all above non-haemodynamic pa-
rameters by several weeks and provides a window of
proactive intervention in order to prevent further ex-
acerbation of HF. In this way, it makes sense that non-
haemodynamic parameters have not made a signifi-
cant impact in remote monitoring of HF patients to
date despite their simplicity and the relatively low ef-
fort involved, for instance in monitoring weight. The
current trial sets out to evaluate the benefit of Car-
dioMEMS remote monitoring versus standard care in
relation to QoL and HF hospitalisations as well as
cost-effectiveness in the Netherlands. If proven ef-
fective, this has important implications for countries
with similar health care structures and levels of HF
care in Western Europe. The field of remote monitor-
ing is most likely to develop further with additional
tools for patient control and pressure feedback with
more sophisticated monitoring websites or tools and
patient self-management. The HF path of care will
evolve into a more structured approach integrating
remote monitoring to achieve a proactive, preventive
approach to patient care instead of passive, symptom-
driven care delivery. Remote monitoring has the po-
tential to lower the overall hospital burden (number
of outpatient visits, admissions and resources used)
of HF in an attempt to keep the stable patient out of
hospital and the unstable patient in hospital only if
refractory to remote interventions at home.
Strengths and limitations
The current trial is important as it is the first ran-
domised clinical trial in Europe comparing haemody-
namic remotemonitoring by CardioMEMS with a con-
trol group in chronic HF. The trial is adequately pow-
ered to test the efficacy of CardioMEMS (in addition
to standard care) in improving QoL and reducing HF
hospitalisations as compared to standard care. Ad-
ditionally, this trial will provide further contemporary
data with CardioMEMS in addition to the CHAMPION
trial and post-marketing registries. As randomisation
is essential in efficacy studies (but lacking in post-
marketing studies), the current European trial is the
first with a control group of standard HF care after the
US CHAMPION trial. This MONITOR HF trial will not
have a sham procedure in consultation with the MEC
and patient councils for a variety of reasons. A sham
procedure and sham measurements every day during
3 years of follow-up was deemed unethical with a fu-
tile risk, patient efforts and costs. Furthermore, we
argue that daily sham measurements (with the sensor
turned off, but with its costs) are not a part of current
standard care and would impact the true compari-
son with standard care as it is actually delivered. We
recognise that the lack of a sham proceduremay intro-
duce a potential bias in the standard care arm. How-
ever, this effect can be of any magnitude, direction
and degree for each individual patient, either positive
or negative (as the technique is most likely not suited
for all), and therefore it will be complex to completely
quantify the placebo effect (and directions). We will
keep precise track of medication changes in response
to abnormal readings of PA pressure and HF admis-
sions as well as detailed records of health care utili-
sation rates, to provide objective proof of subjective
improvements. Finally, despite the mentioned limita-
tions, proactive monitoring and interventions based
upon pre-symptomatic pressure shifts are needed to
achieve any actual sustained benefit of the device.
The design of the current trial and the involvement of
HTA experts from the start of the project ensures high-
quality data for future cost-effectiveness analyses and
modelling from a Western European perspective, in-
cluding detailed health care utilisation data.
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Conclusions
The MONITOR HF randomised clinical trial com-
pares haemodynamic remote monitoring with the
CardioMEMS PA sensor in addition to contempo-
rary standard care versus standard care in improving
QoL and reducing HF hospitalisation in patients with
chronic HF in NYHA class III independent of left
ventricular function. In addition, the study will eval-
uate health care utilisation and cost-effectiveness
in Western Europe from a societal and health care
perspective.
Trial organisation
Project leader and principal investigator
 Dr. J.J. Brugts, ErasmusMCUniversityMedical Cen-
tre (ErasmusMC), Rotterdam
Executive Board
 Prof. Dr. R.A. deBoer, co-chair, UniversitairMedisch
CentrumGroningen (UMCG), Groningen
 Dr. J.J. Brugts, ErasmusMCUniversityMedical Cen-
tre (ErasmusMC), Rotterdam
 Dr. P.P. Delnoy, Isala Klinieken, Zwolle
Steering Committee
 Prof. Dr. R.A. de Boer, voorzitter werkgroep hart-
falen, UMCGGroningen
 Dr. J.J. Brugts, ErasmusMCUniversityMedical Cen-
tre (ErasmusMC), Rotterdam
 Prof. Dr. F.W. Asselbergs, Universitair Medisch Cen-
trum (UMCU), Utrecht
 Prof. Dr. H.P. Brunner-La Rocca, Maastricht Univer-
sitair Medisch Centrum (MUMC),Maastricht
 Dr. J. Borleffs, HAGA ziekenhuis, Den Haag
 Dr. P.P. Delnoy, Isala Klinieken, Zwolle
 Dr. G.C.M. Linssen, Ziekenhuisgroep Twente (ZGT),
Almelo
 Dr. A. Mosterd, Meander MC, Amersfoort
Clinical Epidemiology and Biostatistics, Trial Bureau
Erasmus MC
 Prof. Dr. Ir. H. Boersma, Klinische Epidemiologie en
Biostatistiek, ErasmusMC, Rotterdam
 Dr. M. Lenzen, hoofd Trial Bureau, Klinische Epi-
demiologie, ErasmusMC, Rotterdam
 Dr. J.J. Brugts, ErasmusMCUniversityMedical Cen-
tre (ErasmusMC), Rotterdam
Health Technology Assessment and Health
Economics
 Prof. Dr. M.M. Versteegh, Business Director iMTA
Erasmus Universiteit Rotterdam
 Dr. P.H.M. vanBaal, Erasmus School ofHealth Policy
andManagement Health Economics, Rotterdam
 Dr. H. Koffijberg, Health Technology and Services
Research, Universiteit Twente, Enschede
Acknowledgements We acknowledge all partners and stake-
holders contributing to this project: the Dutch Society of Car-
diology (NVVC), patient councils (Harteraad), and National
Health Care Institute (Zorginstituut) (ZIN) including ZonMW
scientific councils.
Funding The MONITOR HF trial is sponsored by the Dutch
Ministry of Health and National Health Care Institute (Zor-
ginstituut) for reimbursement and conditional coverage of
health-care-related costs and as part of this programme obli-
gatorily sponsored by an independent research grant for
clinical study costs fromAbbott, which has no role in the trial
design, study management, data management analysis or
reporting of the findings.
Conflict of interest J.J. Brugts has received speaker fees from
Abbott and Vifor. M. Versteegh is a member of the EuroQoL
research foundation. W. Kok: has received speaker fees from
Novartis and Roche. S.L.M.A. Beeres is a medical advisor at
the National Health Care Institute (Zorginstituut Nederland).
L. Handoko has received an educational grant from Novartis
(<5kE), as well as speaker’s fees from Novartis, Boehringer-
Ingelheimand Vifor Pharma. F.W. Asselbergs is supported
by UCL Hospitals NIHR Biomedical Research Centre. The
UMCG, which employs R.A. de Boer, has received research
grants and/or fees from AstraZeneca, Abbott, Bristol-Myers
Squibb, Novartis, Novo Nordisk and Roche. R.A. de Boer
is a minority shareholder of scPharmaceuticals and has re-
ceived personal fees from Abbott, AstraZeneca, MandalMed
Inc. and Novartis. J.F. Veenis, S.P. Radhoe, G.C.M. Linssen;
M. van Gent, C.J.W. Borleffs, J. van Ramshorst, P. van Pol,
R. Tukkie, R.F. Spee, M.E. Emans, V. van Halm, M.C. Post,
E. Boersma, M.J. Lenzen, O.C. Manintveld, H. Koffijberg,
P. van Baal, T.D. Smilde, L. van Heerebeek, M. Rienstra,
A. Mosterd, P.P.H. Delnoy and H.P. Brunner-La Rocca declare
that they have no competing interests.
Open Access This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the origi-
nal author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
References
1. De Boer AR, Rutten FH, Valk MJM, Brugts JJ, Deckers JW,
Bots ML, Vaartjes I. Nederlandse Hartstichting 2018. Cij-
fers over risicofactoren, hartinterventies, ziekte en sterfte.
Hartfalen in Nederland, p. 51–79, nov. 2018, Den Haag,
Hartstichting.
2. RIVM.RIVMrapporthartfalen2012: epidemiologie, risico-
factorenentoekomst. 260401006. 2012.
3. Brugts JJ, Linssen GCM, Hoes AW, Brunner-La Rocca HP,
Investigators of CHECK-HF. Real-world heart failureman-
agement in 10,910patientswith chronicheart failure in the
Netherlands: designand rationaleof thechronicheart fail-
ureESCguideline-basedcardiologypracticequalityproject
(CHECK-HF)registry. NethHeartJ.2018;26:272–9.
A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to. . .
Original Article – Design Study Article
4. Brunner-La Rocca HP, Linssen GC, the CHECK-HF inves-
tigators, et al. Contemporary drug treatment of chronic
heart failure with reduced ejection fraction. The CHECK-
HFregistry. JAmCollCardiol. 2019;7:13–21.
5. Greene SJ, Butler J, Albert NM, et al. Medical therapy for
heart failure with reduced ejection fraction: the CHAMP-
HFregistry. JAmCollCardiol. 2018;72:351–66.
6. AngermannCE,StorkS,GelbrichG,etal.Modeofactionand
effects of standardized collaborative diseasemanagement
on mortality and morbidity in patients with systolic heart
failure: the Interdisciplinary Network for Heart Failure
(INH)study. CircHeartFail. 2012;5:25–35.
7. Koehler F, Winkler S, Schieber M, et al. Telemedical
InterventionalMonitoringinHeartFailure(TIM-HF),aran-
domized, controlled intervention trial investigating the
impact of telemedicine on mortality in ambulatory pa-
tients with heart failure: study design. Eur J Heart Fail.
2010;12:1354–62.
8. LyngaP,PerssonH,Hagg-MartinellA,etal.Weightmonitor-
ing in patients with severeheart failure (WISH).A random-
izedcontrolledtrial. EurJHeartFail. 2012;14:438–44.
9. Cleland JG, Louis AA, Rigby AS, et al. Noninvasive home
telemonitoring for patientswith heart failure at high risk of
recurrent admission anddeath: Trans-EuropeanNetwork-
Home-CareManagement System (TEN-HMS) study. J Am
CollCardiol. 2005;45:1654–64.
10. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symp-
tom-guided heart failure therapy: the Trial of Intensified
vs StandardMedical Therapy in Elderly Patients with Con-
gestiveHeart Failure (TIME-CHF) randomized trial. JAMA.
2009;301:383–92.
11. Koehler F, KoehlerK,DeckwartO, et al. Efficacyof telemed-
ical interventionalmanagement in patientswith heart fail-
ure (TIM-HF2): a randomised, controlled, parallel-group,
unmaskedtrial. Lancet. 2018;392:1047–57.
12. Brachmann J, Bohm M, Rybak K, et al. Fluid status mon-
itoring with a wireless network to reduce cardiovascular-
relatedhospitalizationsandmortalityinheartfailure: ratio-
nale and design of the OptiLinkHF Study (Optimization of
HeartFailureManagementusingOptiVolFluidStatusMon-
itoringandCareLink). EurJHeartFail. 2011;13:796–804.
13. van Veldhuisen DJ, Braunschweig F, Conraads V, et al.
Intrathoracic impedance monitoring, audible patient
alerts, and outcome in patients with HF. Circulation.
2011;124:1719–26.
14. Hindricks G, TaborskyM, GliksonM, et al. Implant-based
multiparameter telemonitoring of patients with heart fail-
ure (IN-TIME): a randomised controlled trial. Lancet.
2014;384:583–90.
15. Bohm M, Drexler H, Oswald H, et al. Fluid status
telemedicine alerts for heart failure: a randomized con-
trolledtrial. EurHeartJ.2016;37:3154–63.
16. Abraham WT, Adamson PB, Bourge RC, et al. Wireless
pulmonary artery haemodynamic monitoring in chronic
heart failure: a randomised controlled trial. Lancet.
2011;377:658–66.
17. Abraham WT, Stevenson LW, Bourge RC, et al. Sustained
efficacy of pulmonary artery pressure to guide adjust-
ment of chronic heart failure therapy: complete follow-
up results from the CHAMPION randomised trial. Lancet.
2016;387:453–61.
18. HeywoodJT, JermynR,ShavelleD, etal. Impactofpractice-
basedmanagement of pulmonary artery pressures in 2000
patients implantedwith theCardioMEMS sensor. Circula-
tion. 2017;135:1509–17.
19. Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory
hemodynamic monitoring reduces heart failure hospital-
izations in “real-world” clinical practice. J AmColl Cardiol.
2017;69:2357–65.
20. Shavelle D, Desai AS, Abraham WT, et al. Pulmonary
arterypressure-guidedtherapyforambulatoryheartfailure
patients in clinical practice:1-year outcomes from theCar-
dioMEMS post-approval study. Abstract. AmColl Cardiol
Meet. 2019.
21. Sandhu AT, Goldhaber-Fiebert JD, Owens DK, et al. Cost-
effectiveness of implantable pulmonary artery pressure
monitoring in chronic heart failure. JACC Heart Fail.
2016;4:368–75.
22. CowieMR, SimonM,KleinL, Thokala P. The cost-effective-
ness of real-time pulmonary artery pressuremonitoring in
heart failure patients: a European perspective. Eur J Heart
Fail. 2017;19:661–9.
23. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG,
Coats AJ, et al. 2016 ESC guidelines for the diagnosis and
treatmentofacuteandchronicheartfailure. EurJHeartFail.
2016;18:891–975.
24. Spertus J, Peterson E, Conard MW, Heidenreich PA,
Krumholz HM, Jones P, et al. Cardiovascular outcomes
research consortium. Monitoring clinical changes in
patients with heart failure: a comparison ofmethods. Am
HeartJ.2005;150:707–15.
25. Walters S, Brazier J, et al. Comparison of the minimally
important difference for two health state utility measures:
EQ-5D.QualLifeRes. 2005;101:104–8.
26. Bouwmans C, Hakkaart-van Roijen L, Koopmanschap M,
KrolM, SeverensH,BrouwerW.Handleiding iMTAmedical
cost questionnaire (iMCQ). Rotterdam: iMTA, Erasmus
UniversiteitRotterdam;2013.
27. Rogers JG, et al. Palliative care in heart failure: the PAL-
HF randomized, controlledclinical trial. J AmColl Cardiol.
2017;70:331–41.
28. Kanters TA, Bouwmans CA, van der Linden N, Tan SS,
Hakkaart-van Roijen L. Update of the Dutch manual for
costingstudies inhealthcare. PLoSONE.2017;12:e187477.
29. Jaarsma T, van der Wal M, van Veldhuisen DJ, et al. Effect




30. van Baal PH, Wong A, Slobbe LC, Polder JJ, Brouwer WB,
de Wit GA. Standardizing the inclusion of indirect medi-
cal costs in economic evaluations. PharmacoEconomics.
2011;29(3):175–87.
A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to. . .
